STATEMENT ON SCHEDULE 13D

Company

Vistagen Therapeutics, Inc.

Filed

June 14, 2011

Accession Number

0001222139-11-000008

A Schedule 13D is filed when an investor acquires more than 5% of a company's shares with an intent to influence control. Learn more about SC 13D filings →